Prior to joining AlloVir, Dr. Melian was an SVP in both Global Clinical Development and Medical Sciences at Alexion Pharmaceuticals. During his tenure there, the company achieved record timelines across clinical development including Ultomiris (a >500 patients rare disease development program fully executed from Investigational New Drug (IND) application to filing in <2.5years), 3 successful Biologics License Applications (BLAs) (Strensiq, Kanuma and Ultomiris), a NORD Rare impact award, business acquisitions of Syntimmune, and Wilson Therapeutics, and a quadrupling of the number of products on the market. Dr. Melian also spent 13 years at Merck in a number of clinical development roles, including Product Development Team Leader, Head of Emerging Markets Clinical Development, Head of Japanese Clinical Development, and Head of the Global Medical Organization.
Dr. Melian has a background in DNA transcription and repair. Prior to his industry work, he practiced medicine and conducted Basic Immunology Research at The Brigham and Women’s Hospital in Boston. Dr. Melian graduated cum laude with degrees in Molecular Biophysics and Biochemistry and in Medicine from Yale University.